Company / Free Cash Flow
Kymera Therapeutics, Inc. Free Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$234.3M
FY2025
5-year range
-$234.3M / $17.4M
FY2021-FY2025
Trend
-13.0%
vs FY2024
Sector context
#157 of 194
Health Care
What the data says
Kymera Therapeutics, Inc.'s free cash flow of -$234M is lower than 81% of companies in the Health Care sector (FY2025). Declined from -$137M to -$234M over the past 2 years.
Based on SEC 10-K filings.
-$234M in FY2025.
Declined from -$137M to -$234M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 194This company -$234.3M Sector average $470.8M
▼
-149.8% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 13.0% year-over-year.
- Ranks #157 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$234.3M | -13.0% |
| FY2024 | -$207.3M | -51.0% |
| FY2023 | -$137.3M | +11.9% |
| FY2022 | -$155.9M | -997.5% |
| FY2021 | $17.4M | +0.0% |
| FY2020 | $17.4M | +0.0% |
| FY2019 | $17.4M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026